Vitamin D DeficiencyEVIREST-DNCT01430793
Determination of Effective Vitamin D Replacement and Monitoring Strategies in Vitamin D Deficiency State
A study testing Vitamin D3 600,000 units IM, Vitamin D3 600,000 Orally and Vitamin D3 200,000 units IM in people with Vitamin D Deficiency, run by Aga Khan University at 1 site in Pakistan.
Trial summary
The purpose of the study is determination of effective vitamin D replacement strategy in vitamin D deficiency states with currently available preparations in Pakistan \& to determine the cost effective monitoring strategy with urinary calcium excretion serving as a surrogate marker of achievement of vitamin D… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Vitamin D Deficiency
- What is being tested?
- Vitamin D3 600,000 units IM, Vitamin D3 600,000 Orally and Vitamin D3 200,000 units IM
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 99 participants
- Where
- 1 sitePakistan
- Study dates
- Nov 2011to Mar 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients with Vitamin D level less than 20 ng/dl
Who cannot join
- Patients who have received vitamin D injection in last 03 months.
- Patients with hypercalcemia (corrected calcium > 10.6 mg/dl)
- Known Malignancy.
- Known case of CLD or serum ALT > 3 times ULN
- Patients with creatinine > 2.0 mg/dl.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Vitamin D Dosing and Monitoring Study
The purpose of the study is determination of effective vitamin D replacement strategy in vitamin D deficiency states with currently available preparations in Pakistan \& to determine the cost effective monitoring strategy with urinary calcium excretion serving as a surrogate marker of achievement of vitamin D sufficiency state.
The study will be conducted at the out-patient Endocrinology Clinics of the Aga Khan University Hospital, Karachi, Pakistan. All patients seen in endocrine clinics with Vitamin D level less than 20 ng and do not have any of exclusion criteria mentioned below will be eligible for recruitment in the study. The study participants will be randomly assigned into 4 groups for intervention to receive intramuscular or oral Vitamin D in 200,000 or 600,000 units as per group allocation. Each group will comprise of 25 participants.
Read more
Group 1: Vitamin D3 600,000 units IM and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
Group 2: Vitamin D3 600,000 units orally and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
Group 3: Vitamin D3 200,000 units IM initially and then every 2 monthly for 2 months if levels remain < 30 ng/ml.
Group 4: Vitamin D3 200,000 units orally initially and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
All patients will be prescribed elemental Calcium 1 gram /day. Vitamin D levels along with the other biochemical parameter and random urine for calcium \& creatinine will be checked at 00, 02, 04, 06 and 12 months.
Read the detailed description
Vitamin D deficiency (VDD) has resurfaced as a significant public health problem in recent years. In Pakistan and as well in the region, VDD is very prevalent despite adequate sunshine throughout the year. Prevalence of VDD of 92% and 81% in ambulatory patients has been reported from centers in Karachi and Lahore recently. Reports previously have also demonstrated VDD from various regions of Pakistan, a study conducted at tertiary care hospital in Karachi found that 55% of healthy breast fed infants and 45% of nursing mothers had very low levels of vitamin D. Another study conducted in Hazara division found rickets as a common problem in children despite abundant sunlight.
There are several areas of controversy which has great relevance for the investigators community like what level of vitamin D should be considered as deficiency, what are the daily requirements of vitamin D and how VDD should be corrected. Generally level below 20ng/ml is considered deficient and levels between 21 and 29 ng/ml is considered relative insufficiency as depicted by intestinal calcium absorption and nadir levels of parathyroid hormone.
Determination of the daily intake required to attain adequate serum 25(OH)D concentrations are compounded by the wide variability in the dose-response curve and basal 25(OH)D concentrations.
There is no universally accepted method of correcting VDD, In US the available preparation is 50,000 units of ergocalciferol, given weekly or three times per week for total of 300,000 units. Several strategies has recently been studied, a study from southern Brazil demonstrated that a single 300 000 IU oral dose of vitamin D3 was more effective than 800 IU per day to increase serum 25(OH)D levels in elderly persons, living in a low-income housing unit.
Contrary to this comparison of the equivalent oral doses of vitamin D3 600 IU/day, 4200 IU/week and 18,000 IU/month on vitamin D status showed that daily dose was more effective than a weekly dose, and a monthly dose was the least effective.
In India a recent study evaluated the common physician practice of prescribing 1500 mcg (60 000 IU) cholecalciferol per week for 8 weeks for VDD. Twenty-eight subjects with mean 25 hydoxy vitamin D level of 13.5 nmol/l received oral supplementation of 1500 mcg cholecalciferol per week and 1g elemental Ca daily for 8 weeks. At 8 weeks the vitamin deficiency was corrected in all patients with mean the mean 25(OH)D levels of 82.4 nmol/l however at 1 year follow up all subjects were again vitamin D deficient with the mean 25(OH)D level of 24.7 nmol/l. This suggests that ongoing supplementation after initial loading is needed for sustained improvement in 25(OH)D levels vitamin D levels.
In another study from Australia, a single annual intramuscular injection of 600,000 IU cholecalciferol was administered to 50 vitamin D-deficient participants. Specimens were collected at baseline and after 4 and 12 months of therapy. Serum 25OHD3 levels were significantly higher at 4 months (114 ±35 nmol/L), and 12 months (73 ±13nmol/L) compared with baseline (32 ±8nmol/L) (P < 0.001), increasing by an average of 128% over the 12 months. The therapy was effective, with normalization of serum 25OHD levels and maintenance of a level well above 50nmol/L at 12 months.
In Pakistan oral vitamin D supplementations are available in only in combination with calcium supplement with maximum availability of 400 IU. Two depot intramuscular preparations are available one with 200,000 IU and other with 600,000 IU of vitamin D3. Regarding the 600,000 unit preparation the practices among physician are varied, common practice is to give 600,000 units intramuscularly every 03 months, some physicians prescribe a second injection after first month in cases of severe deficiency and some physicians prescribe 3 injections of Vitamin D at 2 weekly interval and then repeat in 3 months if needed. Regarding the 200,000 unit preparation, it is less commonly used, more expensive than the other preparation; however it has the advantage of using orally as well. There are no published guidelines with these mega doses of depot preparations. The effects of these mega doses have not been studied in the investigators setting and practices are based on individual experiences. The investigators strongly feel that information regarding effective correction of vitamin deficiency with currently available depot preparation is lacking and the investigators study will help in answering this very important and relevant clinical query.
The investigators second objective of the study is to find a cost effective method of monitoring adequacy of vitamin D replacement. While treatment with vitamin D is easy and inexpensive, monitoring of vitamin D levels is expensive, not widely available and assay limitations in terms of precision, accuracy and measurements of status of vitamin D.
The investigators planned to measure urinary calcium excretion as an index of adequacy of vitamin D status and to determine the correlation with vitamin D levels.
Urine calcium is a reflection of dietary intake, calcium absorption from gut, bone turnover, and renal excretion mechanisms. At steady-state excretion is usually approximately 30% of the dietary intake. The efficiency of the absorption of renal calcium and of intestinal calcium and phosphorus is increased in the presence of vitamin D. Reports show increase of intestinal calcium transport by 45 to 65% in women when 25-hydroxyvitamin D levels were increased from an average of 20 to 32 ng per milliliter (50 to 80 nmol per liter).
Calciuria estimated by the calcium/creatinine ratio tended to increase in parallel with 25 OH vitamin D levels this is mostly studied in pediatric population given vitamin D for prophylaxis of rickets. In adult patients with hypercalciuria and renal stone formation positive correlation is seen with vitamin D and urinary calcium excretion. Seasonal variation in vitamin D levels and urinary calcium excretion has also been described. Gokce C et al find significant correlation between random single voided urine calcium-to-creatinine ratio and 24-hour total calcium excretion in 67 subjects who were selected prospectively to represent a wide range of renal and parathyroid function as well as urinary calcium and phosphate loss.
The investigators expect that this simple urine test can be followed to evaluate the vitamin D sufficiency state in post vitamin D treated patients and can serve as a cost effective mean of following these patients.
Objectives:
Primary Objective:
To determine the effect of vitamin D replacement on vitamin D levels with currently available preparations in patients with vitamin D deficiency.
Secondary objective:
To determine the correlation between vitamin D levels and urinary calcium excretion in deficiency and sufficiency states.
- Conditions
- Vitamin D Deficiency
- Being tested
- Vitamin D3 600,000 units IM, Vitamin D3 600,000 Orally, Vitamin D3 200,000 units IM, Vitamin D3 200,000 Orally
- Medical subject headings
- Vitamin D Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin D3 600,000 units IMDrug
Also called Cholecalciferol
Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
Vitamin D3 600,000 OrallyDrug
Also called Cholecalciferol
Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
Vitamin D3 200,000 units IMDrug
Also called Cholecalciferol
Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
Vitamin D3 200,000 OrallyDrug
Also called Cholecalciferol
Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
| Study group | Role | What they receive |
|---|---|---|
| Vitamin D 600,000 IM | Active comparator | Vitamin D3 600,000 units will be given by intramuscular injection Receives: Drug: Vitamin D3 600,000 units IM |
| Vitamin D 600,000 orally | Active comparator | Vitamin D3 600,000 units will be given orally Receives: Drug: Vitamin D3 600,000 Orally |
| Vitamin D 200,000 IM | Active comparator | Vitamin D3 600,000 units will be given by intramuscular injection Receives: Drug: Vitamin D3 200,000 units IM |
| Vitamin D 200,000 orally | Active comparator | Vitamin D 200,000 units will be given orally Receives: Drug: Vitamin D3 200,000 Orally |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in vitamin D levels with specified dose and route of administration, at define intervals
Measured: 02, 04, 06 and12 months
Secondary outcomes (1)
Differences in the random urinary calcium to creatinine ratio in the untreated and treated state and its correlation with vitamin D levels
Measured: 00, 02, 04, 06 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2011 (estimated)
- Study startNov 2011
- Primary completionMar 2013
- Study completionMar 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Vitamin D DeficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 99 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aga Khan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Qamar Masood, Aga Khan University
- Investigators
- Muhammad Q Masood, MBBS; FACP, Principal investigator, Aga Khan UniversityAbdul Jabbar, MBBS; FRCP, Study chair, Aga Khan UniversityAysha Habib, MBBS; FCPS, Study director, Aga Khan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01430793
- Sponsor's protocol ID
- SM100404
- Acronym
- EVIREST-D
- Status last verified
- Apr 2014
- First submitted
- 6 Sep 2011
- Last updated
- 8 Apr 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Masood MQ, Khan A, Awan S, Dar F, Naz S, Naureen G, Saghir S, Jabbar A. COMPARISON OF VITAMIN D REPLACEMENT STRATEGIES WITH HIGH-DOSE INTRAMUSCULAR OR ORAL CHOLECALCIFEROL: A PROSPECTIVE INTERVENTION STUDY. Endocr Pract. 2015 Oct;21(10):1125-33. doi: 10.4158/EP15680.OR. Epub 2015 Jul 7.
PubMed 26151421
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitamin D Dosing and Monitoring Study
- ClinicalTrials.gov ID
- NCT01430793
- Acronym / sponsor ID
- EVIREST-D / SM100404
- Conditions
- Vitamin D Deficiency
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 99 participants (actual)
- Lead sponsor
- Aga Khan UniversityUniversity, hospital or other
- Study start
- Nov 2011
- Primary completion
- Mar 2013 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 8 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is determination of effective vitamin D replacement strategy in vitamin D deficiency states with currently available preparations in Pakistan \& to determine the cost effective monitoring strategy with urinary calcium excretion serving as a surrogate marker of achievement of vitamin D sufficiency state.
The study will be conducted at the out-patient Endocrinology Clinics of the Aga Khan University Hospital, Karachi, Pakistan. All patients seen in endocrine clinics with Vitamin D level less than 20 ng and do not have any of exclusion criteria mentioned below will be eligible for recruitment in the study. The study participants will be randomly assigned into 4 groups for intervention to receive intramuscular or oral Vitamin D in 200,000 or 600,000 units as per group allocation. Each group will comprise of 25 participants.
Group 1: Vitamin D3 600,000 units IM and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
Group 2: Vitamin D3 600,000 units orally and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
Group 3: Vitamin D3 200,000 units IM initially and then every 2 monthly for 2 months if levels remain < 30 ng/ml.
Group 4: Vitamin D3 200,000 units orally initially and then every 2 monthly for 2 times if levels remain < 30 ng/ml.
All patients will be prescribed elemental Calcium 1 gram /day. Vitamin D levels along with the other biochemical parameter and random urine for calcium \& creatinine will be checked at 00, 02, 04, 06 and 12 months.
Detailed description
Vitamin D deficiency (VDD) has resurfaced as a significant public health problem in recent years. In Pakistan and as well in the region, VDD is very prevalent despite adequate sunshine throughout the year. Prevalence of VDD of 92% and 81% in ambulatory patients has been reported from centers in Karachi and Lahore recently. Reports previously have also demonstrated VDD from various regions of Pakistan, a study conducted at tertiary care hospital in Karachi found that 55% of healthy breast fed infants and 45% of nursing mothers had very low levels of vitamin D. Another study conducted in Hazara division found rickets as a common problem in children despite abundant sunlight.
There are several areas of controversy which has great relevance for the investigators community like what level of vitamin D should be considered as deficiency, what are the daily requirements of vitamin D and how VDD should be corrected. Generally level below 20ng/ml is considered deficient and levels between 21 and 29 ng/ml is considered relative insufficiency as depicted by intestinal calcium absorption and nadir levels of parathyroid hormone.
Determination of the daily intake required to attain adequate serum 25(OH)D concentrations are compounded by the wide variability in the dose-response curve and basal 25(OH)D concentrations.
There is no universally accepted method of correcting VDD, In US the available preparation is 50,000 units of ergocalciferol, given weekly or three times per week for total of 300,000 units. Several strategies has recently been studied, a study from southern Brazil demonstrated that a single 300 000 IU oral dose of vitamin D3 was more effective than 800 IU per day to increase serum 25(OH)D levels in elderly persons, living in a low-income housing unit.
Contrary to this comparison of the equivalent oral doses of vitamin D3 600 IU/day, 4200 IU/week and 18,000 IU/month on vitamin D status showed that daily dose was more effective than a weekly dose, and a monthly dose was the least effective.
In India a recent study evaluated the common physician practice of prescribing 1500 mcg (60 000 IU) cholecalciferol per week for 8 weeks for VDD. Twenty-eight subjects with mean 25 hydoxy vitamin D level of 13.5 nmol/l received oral supplementation of 1500 mcg cholecalciferol per week and 1g elemental Ca daily for 8 weeks. At 8 weeks the vitamin deficiency was corrected in all patients with mean the mean 25(OH)D levels of 82.4 nmol/l however at 1 year follow up all subjects were again vitamin D deficient with the mean 25(OH)D level of 24.7 nmol/l. This suggests that ongoing supplementation after initial loading is needed for sustained improvement in 25(OH)D levels vitamin D levels.
In another study from Australia, a single annual intramuscular injection of 600,000 IU cholecalciferol was administered to 50 vitamin D-deficient participants. Specimens were collected at baseline and after 4 and 12 months of therapy. Serum 25OHD3 levels were significantly higher at 4 months (114 ±35 nmol/L), and 12 months (73 ±13nmol/L) compared with baseline (32 ±8nmol/L) (P < 0.001), increasing by an average of 128% over the 12 months. The therapy was effective, with normalization of serum 25OHD levels and maintenance of a level well above 50nmol/L at 12 months.
In Pakistan oral vitamin D supplementations are available in only in combination with calcium supplement with maximum availability of 400 IU. Two depot intramuscular preparations are available one with 200,000 IU and other with 600,000 IU of vitamin D3. Regarding the 600,000 unit preparation the practices among physician are varied, common practice is to give 600,000 units intramuscularly every 03 months, some physicians prescribe a second injection after first month in cases of severe deficiency and some physicians prescribe 3 injections of Vitamin D at 2 weekly interval and then repeat in 3 months if needed. Regarding the 200,000 unit preparation, it is less commonly used, more expensive than the other preparation; however it has the advantage of using orally as well. There are no published guidelines with these mega doses of depot preparations. The effects of these mega doses have not been studied in the investigators setting and practices are based on individual experiences. The investigators strongly feel that information regarding effective correction of vitamin deficiency with currently available depot preparation is lacking and the investigators study will help in answering this very important and relevant clinical query.
The investigators second objective of the study is to find a cost effective method of monitoring adequacy of vitamin D replacement. While treatment with vitamin D is easy and inexpensive, monitoring of vitamin D levels is expensive, not widely available and assay limitations in terms of precision, accuracy and measurements of status of vitamin D.
The investigators planned to measure urinary calcium excretion as an index of adequacy of vitamin D status and to determine the correlation with vitamin D levels.
Urine calcium is a reflection of dietary intake, calcium absorption from gut, bone turnover, and renal excretion mechanisms. At steady-state excretion is usually approximately 30% of the dietary intake. The efficiency of the absorption of renal calcium and of intestinal calcium and phosphorus is increased in the presence of vitamin D. Reports show increase of intestinal calcium transport by 45 to 65% in women when 25-hydroxyvitamin D levels were increased from an average of 20 to 32 ng per milliliter (50 to 80 nmol per liter).
Calciuria estimated by the calcium/creatinine ratio tended to increase in parallel with 25 OH vitamin D levels this is mostly studied in pediatric population given vitamin D for prophylaxis of rickets. In adult patients with hypercalciuria and renal stone formation positive correlation is seen with vitamin D and urinary calcium excretion. Seasonal variation in vitamin D levels and urinary calcium excretion has also been described. Gokce C et al find significant correlation between random single voided urine calcium-to-creatinine ratio and 24-hour total calcium excretion in 67 subjects who were selected prospectively to represent a wide range of renal and parathyroid function as well as urinary calcium and phosphate loss.
The investigators expect that this simple urine test can be followed to evaluate the vitamin D sufficiency state in post vitamin D treated patients and can serve as a cost effective mean of following these patients.
Objectives:
Primary Objective:
To determine the effect of vitamin D replacement on vitamin D levels with currently available preparations in patients with vitamin D deficiency.
Secondary objective:
To determine the correlation between vitamin D levels and urinary calcium excretion in deficiency and sufficiency states.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Vitamin D 600,000 IM | Active comparator | Drug: Vitamin D3 600,000 units IMVitamin D3 600,000 units will be given by intramuscular injection |
| Vitamin D 600,000 orally | Active comparator | Drug: Vitamin D3 600,000 OrallyVitamin D3 600,000 units will be given orally |
| Vitamin D 200,000 IM | Active comparator | Drug: Vitamin D3 200,000 units IMVitamin D3 600,000 units will be given by intramuscular injection |
| Vitamin D 200,000 orally | Active comparator | Drug: Vitamin D3 200,000 OrallyVitamin D 200,000 units will be given orally |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All patients with Vitamin D level less than 20 ng/dl
Key exclusion criteria (5 listed)
- Patients who have received vitamin D injection in last 03 months.
- Patients with hypercalcemia (corrected calcium > 10.6 mg/dl)
- Known Malignancy.
- Known case of CLD or serum ALT > 3 times ULN
- Patients with creatinine > 2.0 mg/dl.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin D3 600,000 units IMAlso: CholecalciferolVitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml | Drug | Vitamin D 600,000 IM |
| Vitamin D3 600,000 OrallyAlso: CholecalciferolVitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml | Drug | Vitamin D 600,000 orally |
| Vitamin D3 200,000 units IMAlso: CholecalciferolVitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml | Drug | Vitamin D 200,000 IM |
| Vitamin D3 200,000 OrallyAlso: CholecalciferolVitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml | Drug | Vitamin D 200,000 orally |
Primary outcome
Change in vitamin D levels with specified dose and route of administration, at define intervals
Time frame: 02, 04, 06 and12 months
1 secondary outcome
Differences in the random urinary calcium to creatinine ratio in the untreated and treated state and its correlation with vitamin D levels
Time frame: 00, 02, 04, 06 and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2014.
- Derived from this study: PubMed 26151421Masood MQ, Khan A, Awan S, Dar F, Naz S, Naureen G, Saghir S, Jabbar A. COMPARISON OF VITAMIN D REPLACEMENT STRATEGIES WITH HIGH-DOSE INTRAMUSCULAR OR ORAL CHOLECALCIFEROL: A PROSPECTIVE INTERVENTION STUDY. Endocr Pract. 2015 Oct;21(10):1125-33. doi: 10.4158/EP15680.OR. Epub 2015 Jul 7.
Related trials for Vitamin D Deficiency
RecruitingPhase 1/2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
X-linked Hypophosphatemia
Not yet recruitingPhase 2
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial
Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function
Recruiting
Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS), Vitamin D Deficiency
RecruitingObservational study
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
FGF23-related Hypophosphataemic Rickets and Osteomalacia
Not yet recruiting
Effect of Vitamin D Supplementation Added to Iron Therapy in Children With Iron Deficiency Anemia
Iron Deficiency Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Muhammad Q Masood, MBBS; FACP principal investigator
Aga Khan University
Abdul Jabbar, MBBS; FRCP study chair
Aga Khan University
Aysha Habib, MBBS; FCPS study director
Aga Khan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin D3 600,000 units IM, Vitamin D3 600,000 Orally and Vitamin D3 200,000 units IM in people with Vitamin D Deficiency, run by Aga Khan University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in vitamin D levels with specified dose and route of administration, at define intervals (time frame: 02, 04, 06 and12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01430793, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2014.